Catalio Capital Management LP Grows Position in Eledon Pharmaceuticals, Inc. $ELDN

Posted by Geri Gentry on Jun 18th, 2026

Catalio Capital Management LP grew its position in shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN – Free Report) by 18.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,259,820 shares of the company’s stock after purchasing an additional 198,688 shares during the quarter. Catalio Capital Management LP owned approximately 2.10% of Eledon Pharmaceuticals worth $1,902,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of ELDN. ADAR1 Capital Management LLC bought a new position in Eledon Pharmaceuticals during the 4th quarter worth approximately $2,751,000. Jefferies Financial Group Inc. purchased a new stake in Eledon Pharmaceuticals in the 4th quarter worth approximately $2,387,000. Ensign Peak Advisors Inc lifted its stake in shares of Eledon Pharmaceuticals by 94.9% in the 4th quarter. Ensign Peak Advisors Inc now owns 2,464,919 shares of the company’s stock valued at $3,722,000 after purchasing an additional 1,200,000 shares during the period. AWM Investment Company Inc. purchased a new position in shares of Eledon Pharmaceuticals in the 4th quarter valued at approximately $1,661,000. Finally, Blue Owl Capital Holdings LP lifted its stake in shares of Eledon Pharmaceuticals by 96.9% in the 4th quarter. Blue Owl Capital Holdings LP now owns 1,929,912 shares of the company’s stock valued at $2,914,000 after purchasing an additional 950,000 shares during the period. 56.77% of the stock is currently owned by institutional investors.

Eledon Pharmaceuticals Stock Performance

NASDAQ ELDN opened at $3.70 on Thursday. The company has a market capitalization of $285.60 million, a PE ratio of -4.81 and a beta of 0.94. The business’s fifty day moving average is $3.64 and its 200 day moving average is $2.69. Eledon Pharmaceuticals, Inc. has a fifty-two week low of $1.35 and a fifty-two week high of $4.60.

Eledon Pharmaceuticals (NASDAQ:ELDN – Get Free Report) last posted its earnings results on Wednesday, May 13th. The company reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.11). On average, sell-side analysts forecast that Eledon Pharmaceuticals, Inc. will post -0.74 EPS for the current year.

Analyst Ratings Changes

ELDN has been the subject of a number of recent research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eledon Pharmaceuticals in a research note on Friday, March 27th. Wall Street Zen cut Eledon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 16th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $9.67.

Check Out Our Latest Report on Eledon Pharmaceuticals

Eledon Pharmaceuticals Profile

(Free Report)

Eledon Pharmaceuticals, Inc (NASDAQ:ELDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of therapies for diseases characterized by smooth muscle dysfunction. The company leverages a proprietary ion-channel modulation platform to identify and optimize small-molecule compounds that can either restore or inhibit smooth muscle activity, with the goal of addressing gastrointestinal, hepatic and cardiovascular disorders.

Eledon’s pipeline comprises several preclinical and early-phase clinical programs targeting high-unmet-need indications.